cd19 polyclonal antibody  (Proteintech)

Journal: Arthritis Research & Therapy

Article Title: IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis

doi: 10.1186/s13075-026-03735-8

Figure Lengend Snippet: Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

Article Snippet: The following reagents were used: Rat polyclonal CD19 antibody (Columbia, MD, USA; Cat# 32727), a Mouse IL-6 antibody (Santa Cruz Biotechnology, USA; Cat# SC-28343), Mouse monoclonal CD19 antibody (Novus Biologicals, USA; Cat# NBP2-25196SS), Rat Anti-IL-10 antibody (Abcam, Cambridge, UK; Cat# ab133575), and Rat IL-35 Antibody (Abbexa, Cambridge, UK; Cat# Abx274658),

Techniques: Expressing, Flow Cytometry, Staining, Clinical Proteomics, Immunofluorescence

Journal: Arthritis Research & Therapy

Article Title: IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis

doi: 10.1186/s13075-026-03735-8

Figure Lengend Snippet: Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

Article Snippet: The following reagents were used: Rat polyclonal CD19 antibody (Columbia, MD, USA; Cat# 32727), a Mouse IL-6 antibody (Santa Cruz Biotechnology, USA; Cat# SC-28343), Mouse monoclonal CD19 antibody (Novus Biologicals, USA; Cat# NBP2-25196SS), Rat Anti-IL-10 antibody (Abcam, Cambridge, UK; Cat# ab133575), and Rat IL-35 Antibody (Abbexa, Cambridge, UK; Cat# Abx274658),

Techniques: Expressing, Flow Cytometry, Staining, Clinical Proteomics, Immunofluorescence

Journal: Cell Reports Medicine

Article Title: Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection

doi: 10.1016/j.xcrm.2025.102458

Figure Lengend Snippet: BiTEs provided treatment effects against lethal SFTSV infection through improving T cell cytotoxicity in vivo (A) Percentage of CD45 + T cells, CD4 + T cells, CD8 + T cells, CD19 + B cells, CD11b + Gr-1 + neutrophils, and Foxp3 + Tregs in spleen samples collected at 6 dpi from mice ( n = 5 per group) measured by flow cytometry. (B) A schematic diagram showing depletion of T cells in mice to determine the role of T cells in 3A5 BiTE treatment. Six- to eight-week-old male humanized CD3e C57BL/6 mice were pretreated with anti-IFNAR1 antibody (300 μg per mouse) and then intraperitoneally inoculated with SFTSV (2 × 10 4 PFUs per mouse) one day later. One day after viral infection, mice were intraperitoneally injected with 3A5 BiTE (10 mg/kg for each mouse) or an equal volume of PBS. Anti-mouse CD4 and CD8a antibodies were used for depletion of T cells. (C) Survival curves of SFTSV-challenged mice treated with PBS ( n = 12) or 3A5 BiTE ( n = 12) and mice treated with 3A5 BiTE and depleted with CD4 + or CD8 + T cells ( n = 7). Death is defined as a humane endpoint when animals lost ≥20% body weight but not natural death. (D) Viral titers in spleen samples from mice measured by immunological focus assay, at 6 days post-infection (dpi). (E) Representative images of spleen sections collected at 6 dpi stained with hematoxylin and eosin (H&E) or with an antibody against SFTSV NP. Scale bars, 100 μm. See also . Data were presented as mean ± SD (A and D). One-way ANOVA followed by Tukey’s multiple comparisons test was performed for comparison of continuous variables among multiple groups (A and D). The Kaplan-Meier method was used to analyze time-to-event data (C). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ns: no significance.

Article Snippet: CD19 polyclonal antibody , Signalway Antibody , Cat# 41946 RRID: AB_2933698.

Techniques: Infection, In Vivo, Flow Cytometry, Injection, Staining, Comparison

Journal: Cell Reports Medicine

Article Title: Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection

doi: 10.1016/j.xcrm.2025.102458

Figure Lengend Snippet: scRNA-seq analysis of splenocytes from mice treated with 3A5 BiTE (A) Immune cells of the spleen from SFTSV-infected mice following treatment with control BiTE or 3A5 BiTE were isolated for scRNA-seq analysis ( n = 3 per group). The UMAP plot displays all the immune cells from the two groups, colored by eight major cell types. (B) Proportion of the eight major cell types in the control BiTE group and 3A5 BiTE group. (C) Violin plots show cytotoxicity (left) and exhaustion (right) module score for CD4 + T ( n = 936 and n = 532) and CD8 + T ( n = 1997 and n = 1174) cells in the 3A5 BiTE-treated group and the control group, respectively. The horizontal lines display the 25 th , 50 th (median), and 75 th percentiles. The cytotoxicity module score was calculated based on the expression levels of Gzma, Gzmb, Gzmk, Gzmc, Gzmm, Gzmf, Ifng, Nkg7, Prf1, Ccl4, and Ccl5. The exhaustion module score was calculated based on the expression levels of Pdcd1, Lag3, Ctla4, Havcr2, and Tnfrsf9. A two-tailed t test was performed to analyze the differences between two groups. ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns: no significance. (D) The UMAP plot displays T cells colored by 10 T cell subsets. (E) The bubble plot shows expression of well-documented marker genes in T cell subsets. Dot size represents gene expression percentage per cell type, with marker gene intensity displayed. (F) Comparison of the proportions of T cell subsets between control BiTE group and 3A5 BiTE group. Data were presented as mean ± SD Mann-Whitney test was used for comparisons of values among two groups. ∗ p < 0.05; ∗∗ p < 0.01; ns: no significance. (G) Heatmap of GSEA pathway enrichment scores of individual T cell clusters between 3A5 BiTE and control BiTE groups. (H) A circle plot showing differential interaction strength among CD4 + T cells, CD8 + T cells, B cells, and plasma cells across two groups. Red edges indicate stronger interactions in the 3A5 BiTE group in comparison with control BiTE group, while blue edges indicate stronger interactions in the control BiTE group compared with 3A5 BiTE group. (I) Spleen sections collected from 3A5 BiTE- and control BiTE-treated mice at 6 days post-infection were subjected to co-immunofluorescence staining using anti-CD4 and anti-CD19 antibodies. Scale bars, 100 μm. See also and .

Article Snippet: CD19 polyclonal antibody , Signalway Antibody , Cat# 41946 RRID: AB_2933698.

Techniques: Infection, Control, Isolation, Expressing, Two Tailed Test, Marker, Gene Expression, Comparison, MANN-WHITNEY, Clinical Proteomics, Immunofluorescence, Staining